FY2026 EPS Estimates for REGENXBIO Cut by HC Wainwright

REGENXBIO Inc. (NASDAQ:RGNX) – Investment analysts at HC Wainwright lowered their FY2026 earnings estimates for REGENXBIO in a research note issued on Friday, June 5th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings per share of ($3.86) for the year, down from their prior estimate of ($3.38). HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($3.59) per share. HC Wainwright also issued estimates for REGENXBIO’s Q4 2026 earnings at ($1.22) EPS, Q1 2027 earnings at ($1.13) EPS, Q2 2027 earnings at ($1.03) EPS, Q3 2027 earnings at ($0.98) EPS and Q4 2027 earnings at ($0.93) EPS.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). REGENXBIO had a negative net margin of 330.23% and a negative return on equity of 232.50%. The company had revenue of $6.39 million during the quarter, compared to analysts’ expectations of $25.84 million.

A number of other brokerages have also recently issued reports on RGNX. Bank of America dropped their target price on shares of REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a report on Friday, May 15th. Robert W. Baird set a $27.00 price objective on shares of REGENXBIO in a research note on Tuesday, February 10th. Chardan Capital dropped their price objective on shares of REGENXBIO from $52.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Barclays dropped their price objective on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, May 15th. Finally, Morgan Stanley set a $16.00 price objective on shares of REGENXBIO in a research note on Friday, May 15th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.55.

REGENXBIO Trading Up 0.8%

Shares of REGENXBIO stock opened at $6.13 on Tuesday. REGENXBIO has a 12-month low of $5.45 and a 12-month high of $16.19. The stock has a market cap of $316.92 million, a PE ratio of -1.09 and a beta of 1.04. The company has a 50-day moving average of $8.12 and a two-hundred day moving average of $10.37.

Insider Buying and Selling at REGENXBIO

In other news, insider Steve Pakola sold 15,309 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $11.02, for a total transaction of $168,705.18. Following the completion of the transaction, the insider directly owned 232,617 shares of the company’s stock, valued at $2,563,439.34. This trade represents a 6.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.22% of the stock is currently owned by company insiders.

Institutional Trading of REGENXBIO

Hedge funds have recently bought and sold shares of the company. Aquatic Capital Management LLC acquired a new stake in REGENXBIO during the third quarter worth approximately $37,000. Jones Financial Companies Lllp boosted its position in REGENXBIO by 44.4% during the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares during the last quarter. Captrust Financial Advisors acquired a new stake in REGENXBIO during the second quarter worth approximately $85,000. Entropy Technologies LP acquired a new stake in REGENXBIO during the first quarter worth approximately $87,000. Finally, Prudential Financial Inc. acquired a new stake in REGENXBIO during the second quarter worth approximately $87,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.